Viewpoint discusses clinical trial results of GLP-1 receptor agonists for treating the weight gain and cardiovascular disease risk of psychiatric medications. ja.ma/4hzfSFFpic.twitter.com/YqeZH1RZN0
Teacher, Clinical Supervisor, [AIdvisor]
Retired Clinical Associate Professor, Psychiatry, University of Florida
Affiliation is for identification only. All content and opinions are my own.
View more posts
Gator Psychiatry 